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Lipoprotein-Associated Phospholipase A2 and the Young Adult
Inflammatory biomarkers have been inadequate in predicting heart attacks and strokes.
Many of these markers also lack specificity as they are affected by multiple factors. Science is
still evolving as the relationship between chronic inflammation and atherosclerosis has only been
discovered and studied in recent decades, and so these inflammatory markers are continuing to
be identified and developed. There is a growing panel of indicators for cardiovascular disease
(CVD) and risk, and the newer markers are filling the need to test for more precise pathological
conditions.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a newer, vascular-specific
inflammatory marker that has been shown to distinguish rupture-prone plaque. It is a unique
phospholipase A2 enzyme produced in the plaque of inflamed arterial walls predominantly by
macrophages, but also other inflammatory cells. It binds with lipoproteins, mostly low-density,
and it initiates hydrolysis of oxidized phospholipids in LDL releasing the inflammatory
lysophosphatidylcholine (Lyso-PC) and oxidized free fatty acids (Mallat, Lambeau, & Tedgui,
2010). Higher levels of Lp-PLA2 indicate higher chances of plaque rupture, which causes most
cardiovascular events (Falk, Shah, & Fuster, 1995; Mauriello et al., 2010). A consensus panel
recommended that Lp-PLA2 levels >200 ng/mL be considered to increase Framingham risk
scores after finding that they doubled the risk of heart attack and stroke (Davidson et al., 2008).
The PLAC® Test measures Lp-PLA2 levels and is suggested for patients who have any
risk factors or need a routine lipid panel done. The test received market clearance by the FDA in
2003, and in December of 2014, it was approved as a screening test for all adults, even those
with no history of coronary artery disease (CAD). The American Heart Association, the
American Stroke Association, the American College of Cardiology Foundation, and the
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American Association of Clinical Endocrinologists all include Lp-PLA2 in their guidelines
(Greenland et al., 2010; Jellinger et al., 2012; Meschia et al., 2014).
The impact of more specific testing has the potential for great significance. According to
the World Health Organization (WHO, 2015), CVD is the number one killer in the United States
and globally, and CAD is the most common and deadly type. Here in America, someone has a
myocardial infarction (MI) every 43 seconds (Mozaffarian et al., 2015). Only screening patients
by checking their lipids is no longer adequate. At least one analysis of hospitalized patients with
CAD revealed that about half of those having a MI had normal cholesterol (Sachdeva et al.,
2009). Conversely, a number of patients (5-20%) with spontaneous MI have minimal or even no
CAD (Thygesen et al., 2012). These last points underline not only the need for greater
specificity, but also the need to recognize modifiable risk factors to aid in prevention through
lifestyle changes.
Cardiovascular risk factors are developing at increasingly earlier ages as the diet and
lifestyle of America’s young adults are becoming unhealthier with each generation. The
American Heart Association reveals that modifiable factors such as obesity, hypertension, high
cholesterol, and diabetes are being diagnosed progressively earlier in life (Mozaffarian et al.,
2015). Compounding this, when compared with older adults, young people are less aware of
their health status, less aware that it impacts their future health, and less likely to attribute any
early warning signs to a chronic disease. One study showed that while age-adjusted mortality
from CAD declined steadily from 1980 to 2002, the declines in age-specific mortality started
leveling off for young adults, and actually increased from 1997 to 2002 for women in the 35-44
age group (Ford & Capewell, 2007). More recently, Gupta et al. (2014) found that deaths from
acute MI decreased for young women from 2001 to 2010, but hospitalization rates for MI in this
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time period stayed the same for young men and women. This long-standing lack of improvement
in occurrence highlights that the younger population is insufficiently targeted in primary care and
prevention.
There is a limited amount of research on CAD in young adults. The literature review will
introduce the pivotal findings on the relationship between CAD and Lp-PLA2, and explore the
lifestyle connection that is relatable to the younger population. Possible treatment options
through lifestyle changes, and also medicines, are reviewed as well for those with elevated
enzyme levels. Following the literature review, this current analysis will look at Lp-PLA2 in a
specific study done on a college-aged population with the purpose of examining the significance
of the available cross-sectional data on PLAC scores in young adults. Research assistant
activities are also described.
Literature Review
Establishment of Clinical Significance
Checking Lp-PLA2 levels in patients may be a newer idea, but the relationship between
this enzyme and indicators of cardiovascular disease has been recognized and studied since the
1980s (Farr, Cox, Wardlow, & Jorgensen, 1980; Ostermann et al., 1988; Steinbrecher &
Pritchard, 1989). In 2000, The New England Journal of Medicine published an analysis from the
West of Scotland Coronary Prevention Study (WOSCOPS) that showed for the first time that LpPLA2 not only had a strong association with CAD, but also was statistically independent of other
inflammatory markers and CAD risk factors (Packard et al., 2000). By 2010, The Lp-PLA2
Studies Collaboration published a meta-analysis in The Lancet of 32 prospective studies, which
contained over 95% of the pertinent information on Lp-PLA2. They concluded that Lp-PLA2
positively correlated with other inflammatory markers, was associated with CVD in the same
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way as non-HDL and systolic blood pressure, and could give distinct insight due to being
independent of other markers and risk factors (Thompson et al., 2010). Since this time, the
research on Lp-PLA2 has grown exponentially and clinical utilization is starting to increase.
Non-Pharmaceutical Means of Improvement
Many lifestyle choices are made early in life and continue through adulthood. Berenson
et al. (1998) showed through autopsies that even children and young adults had atherosclerosis
that worsened as the number of cardiovascular risk factors increased. The risk factors of high
cholesterol, high blood pressure, poor nutrition, inactivity, obesity, diabetes, excessive alcohol,
stress, and smoking are all modifiable through lifestyle changes. Therapeutic changes have been
shown to prevent and reverse the effects of CAD. Research is now emerging to support that
improving these factors also improves Lp-PLA2 levels. The following are some examples of diet
and lifestyle changes affecting this inflammatory marker.
Obesity. Tzotzas el al. (2007) studied obese women without CVD and showed that a lowcalorie diet not only lowered weight but also lowered Lp-PLA2. The intervention included young
adults with ages ranging from 18 to 63. After four months, a 10.3% reduction in the women’s
weight resulted in a 10.2% reduction in Lp-PLA2 activity (p < .01). Interestingly, the only
correlation was with VLDL mass (r = .39, p < .05) through the weight loss and not LDL or
sdLDL, which are typically more associated with Lp-PLA2 (Tzotzas et al., 2007).
Diet and exercise. The confounder of weight was kept in check when a group of HIV
patients receiving highly active antiretroviral therapy (HAART) were considered for a study on
the impacts of lifestyle modification on Lp-PLA2 due to their increased inflammatory state
(Wooten et al., 2013). Young adults, with a minimum age of 21, were included. The participants
were randomized into five groups: 1) usual care with two placebos, 2) intensive diet and exercise
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(D/E) with two placebos, 3) D/E with active fenofibrate and niacin placebo, 4) D/E with active
niacin and fenofibrate placebo, and 5) D/E with active fenofibrate and active niacin. Weight and
BMI remained constant through the adjustments of dieticians. After 24 weeks, when compared to
the usual care group, Lp-PLA2 was significantly lower in groups 2 (p < .05), 3 (p < .05), and 4 (p
< .01). Although group 5 did not receive this improvement for Lp-PLA2, they were the only
group to have significant reductions in triglycerides (p < .01), non-HDL (p < .05), and TC:HDL
ratio (p < .01), along with an increase in HDL (p < .01) when compared to the usual care group
(Wooten et al., 2013). These results argue that Lp-PLA2 may be lowered through diet and
exercise alone, regardless of weight loss or a change in BMI.
Not all have been successful in altering the level through dietary means, however. One
example is a group that found no effect when giving various amounts of fish and olive oils to
their subjects (Pedersen, Koenig, Christensen, & Schmidt, 2009). Further research is needed on
specific diets to find the desired effects on Lp-PLA2.
Nutrition. In a cardiovascular sub-cohort of the ongoing Malmö Diet and Cancer study in
Sweden, Hlebowicz et al. (2011) examined associations between food patterns, inflammatory
markers, and CVD. They narrowed the energy from food consumption, representative of their
large sample size, down to six clusters labeled “‘many foods and drinks (MFD),’ ‘fibre bread,’
‘low fat and high fibre (LFHF),’ ‘white bread,’ ‘milk fat’ and ‘sweets and cakes’” (Hlebowicz et
al., 2011, p. 367). In studying Lp-PLA2, they looked at mass and activity. For Lp-PLA2 mass (ng
mL-1), the highest level was in the ‘milk fat’ cluster for women (M = 269.25, SE = 4.23) and men
(M = 308.03, SE = 4.84), and the lowest was in the ‘LFHF’ cluster for women (M = 250.64, SE =
3.26) and men (M = 284.55, SE = 6.97). For women, Lp-PLA2 mass was also elevated with high
sugar consumption, and at a 13-year follow-up, there was increased CVD in the ‘milk fat’ (HR
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2.20, 95% CI [1.09, 4.44]) and ‘sweets and cakes’ (HR 2.14, 95% CI [1.17, 3.93]) clusters. Other
significant findings were that for men, Lp-PLA2 activity (ng mL-1) was best in ‘LFHF’ (M =
47.58, SE = 1.13), and for women, it was worst in ‘white bread’ (M = 44.06, SE = 0.70). They
conclude that the best diet for inflammatory markers, and possibly CVD risk, is high in fiber and
low in fat and sugar (Hlebowicz et al., 2011).
Smoking, drinking, cholesterol, and diet again. Hatoum, Nelson, Cook, Hu, and Rimm
(2010) researched women from the Nurses’ Health Study (NHS) and men from the Health
Professionals Follow-Up Study (HPFS), looking at a variety of factors in those without CAD or
cancer. They analyzed the cross-sectional data of laboratory values and lifestyle measurements,
and the combined results found that having a BMI between 25-29.9 kg/m2 (p < .001), having
high cholesterol (p < .001), taking aspirin (p < .01), and smoking (p < .001) were all significantly
associated with elevated levels of Lp-PLA2. Drinking a moderate amount of alcohol lowered LpPLA2 (p < .001). In women, postmenopausal hormone use was also associated with a lower level
(p < .001). The study found that cholesterol-lowering medication only lowered Lp-PLA2 in those
with a history of high cholesterol (p < .05), and it actually appeared to raise the level in the small
number that took medication without a history of high cholesterol. Another interesting dietary
finding was that replacing carbohydrate consumption with protein was associated with decreased
Lp-PLA2 activity (p < .05), and more importantly, that protein appeared to have an effect on LpPLA2 unrelated to the expected changes in lipid concentrations (Hatoum et al., 2010).
Pharmaceutical Means of Improvement
While lifestyle changes are effective for many, those at increased risk may need help
through medications. Statins have been shown to lower Lp-PLA2 levels, at least in those with
elevated cholesterol (Hatoum et al., 2010). Results from an analysis of the Long-Term
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Intervention with Pravastatin in Ischaemic Disease (LIPID) study revealed that pravastatin
reduced the level by 16% after one year while the placebo reduced it by 0.4% (p < .001). More
importantly, this was found to have an equal or greater impact than LDL reduction on CHD
death and heart attacks (White et al., 2013). Ryu et al. (2012) did a substudy of the Myocardial
Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial and found that
atorvastatin lowered median Lp-PLA2 mass (-35.8%) and activity (-24.3%) more than a placebo
(-6.2%, 5.4% respectively; p < .001) after just 16 weeks on an 80 mg dose. Rosuvastatin has also
displayed good results, along with ezetimibe and fenofibrate (Agouridis et al., 2011; Saougos et
al., 2007). The Lp-PLA2 inhibitor darapladib failed the STABILITY and SOLID-TIMI 52 trials
over the past couple of years leaving out the option for now of a specific Lp-PLA2-lowering drug
(O’Donoghue et al., 2014; White et al., 2014).
Summary
Lp-PLA2 has been established as a critical inflammatory biomarker. Basic lipid panels
are becoming insufficient to test for CVD. Half of those having a MI have normal cholesterol
(Sachdeva et al., 2009). While there is more research on pharmaceutical methods of treatment for
elevated levels of Lp-PLA2, the available diet and lifestyle studies show that there is at least
some degree of relationship in these areas. For young adults, this is a good place to begin when
discussing prevention and early treatment options. It has been shown that Lp-PLA2 activity has a
positive association with age (Hatoum et al., 2010). Even for those that will not experience a
cardiovascular event when they are young, their current lifestyle choices are known
prognosticators for having one later in life. The chronic and progressive inflammatory
characteristics of disease point to a correlation with lifestyle factors and the need for earlier
primary prevention.
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Methodology
In 2014, research was conducted on student volunteers of the Zoe Transformation, a 28day wellness challenge that took place at Southern Adventist University (SAU). The purpose of
the study was to examine the effects of a whole-food plant-based diet on cardiovascular markers
and spirituality. Among the laboratory values, levels of Lp-PLA2 were examined by measuring
PLAC scores before and after the 28-day period. The researchers also used various
questionnaires, scales, and interviews. They hypothesized that the tests and measurements would
improve over the study period, and the spiritual component would enhance the participants’
resolve during the challenge.
Theoretical Framework
The SAU School of Nursing utilizes the Neuman Systems Model (NSM) for its emphasis on a
comprehensive view of health. The NSM is also appropriate as a theoretical framework for the
Zoe Transformation with its focus on prevention and health promotion. The individual
participants’ stressors and environments were factored into the study, consistent with the model.
Neuman’s physiological, psychological, sociocultural, developmental, and spiritual variables
were all addressed in the challenge (Neuman, 2005). The Zoe study evaluates the effects of
lifestyle elements (diet, stress, physical activity, spirituality, etc.) on the health of college
students.
Design
For this exploratory quasi-experimental study, a pre-test/post-test was used to evaluate
the effects of a faith-based, 28-day lifestyle transformation program on cardiovascular markers
and spirituality.
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Sample
Any SAU student that was registered at the time of the study was permitted to participate.
Volunteers were recruited by email and also by a verbal presentation at the program launch.
There were a total of 79 student participants. The experimental group contained 52 subjects, and
the control group contained 27. Of the total, 19 individuals (10 experimental, 9 control) had their
Lp-PLA2 checked with the PLAC Test at the beginning of the study (Pre-PLAC), and 13 (8
experimental, 5 control) checked it at the end (Post-PLAC). All that had a Post-PLAC drawn
were from the 19 that had a Pre-PLAC done, except for one subject in the experimental group.
Tools
The researchers used various tests, self-reporting scales and questionnaires, and
interviews to collect information at the beginning and end of the study. The resting metabolic
rate was tested by the Parvo Medics TrueOne 2400 Metabolic Measurement System in the SAU
Human Performance Lab under the supervision of Dr. Harold Mayer. Blood tests used were
plasma cortisol levels, C-reactive protein, lipids, and PLAC. These samples were collected by
the researchers and taken to University Health Services for processing by PathLab. The Dietary
Screener Questionnaire (DSQ), containing 30 questions, gathered information on each
participant’s food group selection and frequency for the previous month. The Short Last 7 Days
Self-Administered version of the International Physical Activity Questionnaire (IPAQ) was used
to evaluate activity level in seven questions covering the vigorous, moderate, light, and sedentary
categories. The 14-question Perceived Stress Scale (PSS) measured the response to specific
stressors over the past month. The Daily Spiritual Experience Scale (DSES) was the first tool
used for the spiritual component of the study with its 15 items assessing the influence of God in
everyday life. The interviews were the other method by which the spiritual experience was
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explored. These were only done at the end of the 28-day period and contained four open-ended
questions.
Ethics
The SAU Institutional Review Board approved the research project. Efforts were made to
keep personal information confidential, and no personal identifiers were collected. Identifiers
were translated to a code, and letter identifiers were used for the interviews. The potential
physical and psychological risks from the tests were considered minimal. Participation was
voluntary and students were able to choose which components to engage in. Informed consent
was obtained from all participants.
Analysis
All analyses were performed using SPSS version 22. A p value less than .05 was
considered to be statistically significant.
Results and Discussion
Research Assistant
As a research assistant, my initial involvement was compiling and increasing the
available research on Lp-PLA2 for the School of Nursing at Southern Adventist University. An
emphasis was placed on articles that showed a relationship between Lp-PLA2 and lifestyle, as
this area was found most lacking. Research was also sought out that was directed towards, or
included, young adults. The other main area of work as research assistant included assumption
and correlation testing on ZOE cross-sectional PLAC data using SPSS.
Findings
The ZOE study is nearing completion, but the data analysis was still ongoing at the time
this paper was submitted.
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Evaluation
There was a clear benefit from working in a focused area of study over an extended
period of time. A greater understanding of Lp-PLA2 was obtained in this process, and also a
small glimpse of the complex, pervasive condition of chronic inflammation. The ZOE study has
been unique with its utilization of graduate students, which has changed the hands of those
working on different components as each semester progresses. The efforts and sacrifices of
individuals working on a research team have been increasingly recognized and valued by the
successive participants.
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